CoChat

Humoral Response Dynamics Following Infection with SARS-CoV-2

Open access
Grandjean, Louis, Saso, Anja, Torres, Arturo, Lam, Tanya, Hatcher, James, Thistlethwayte, Rosie, Harris, Mark, Best, Timothy, Johnson, Marina, Wagstaffe, Helen, Ralph, Elizabeth, Mai, Annabelle, Colijn, Caroline, Breuer, Judith, Buckland, Matthew, Gilmour, Kimberly, Goldblatt, David, the Co-Stars Study Team · 2020 · medRxiv
PreprintCited by 45

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Introduction: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) specific antibodies have been shown to neutralize the virus in-vitro. Understanding antibody dynamics following SARS-CoV-2 infection is therefore crucial. Sensitive measurement of SARS-CoV-2 antibodies is also vital for large seroprevalence surveys which inform government policies and public health interventions. However, rapidly waning antibodies following SARS-CoV-2 infection could jeopardize the sensitivity of serological testing on which these surveys depend. Methods: This prospective cohort study of SARS-CoV-2 humoral dynamics in a central London hospital analyzed 137 serial samples collected from 67 participants seropositive to SARS-CoV-2 by the Meso-Scale Discovery assay. Antibody titers were quantified to the SARS-CoV-2 nucleoprotein (N), spike (S-)protein and the receptor-binding-domain (RBD) of the S-protein. Titers were log-transformed and a multivariate log-linear model with time-since-infection and clinical variables was fitted by Bayesian methods. Results: The mean estimated half-life of the N-antibody was 52 days (95% CI 42-65). The S- and RBD-antibody had significantly longer mean half-lives of 81 days (95% CI 61-111) and 83 days (95% CI 55-137) respectively. An ACE-2-receptor competition assay demonstrated significant correlation between the S and RBD-antibody titers and ACE2-receptor blocking in-vitro. The time-to-a-negative N-antibody test for 50% of the seropositive population was predicted to be 195 days (95% CI 163-236). Discussion: After SARS-CoV-2 infection, the predicted half-life of N-antibody was 52 days with 50% of seropositive participants becoming seronegative to this antibody at 195 days. Widely used serological tests that depend on the N-antibody will therefore significantly underestimate the prevalence of infection following the majority of infections. Significance statement: We believe that our study has significant and urgent public health and translational impact. Firstly, our findings demonstrate that the half-life of the SARS-CoV-2 nucleoprotein antibody is only 52 days. This has immediate and important implications for large-scale seroprevalence surveys, government policy and mathematical modelling predictions which rely on serological tests that target this antibody. Secondly, the slower decay of the SARS-CoV-2 spike protein antibody identified in this study makes assays to the spike protein a more reliable target for serological assays in the longer term. We demonstrate a strong positive linear correlation between spike/RBD antibody and ACE-2 receptor binding in vitro. Our findings are therefore likely to reflect the time to loss of a functional antibody response in SARS-CoV-2. Funding: GOSH charity, Wellcome Trust (201470/Z/16/Z and 220565/Z/20/Z). GOSH NIHR Funded Biomedical Research Centre. Trial registration number: NCT04380896.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.07.16.20155663

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 21

  1. 10.1056/NEJMoa2002032 · DOI · Paper page
  2. 10.1056/NEJMoa2001017 · DOI · Paper page
  3. Y. Cong , et al., Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. Journal of Virology 94 (2019). · DOI · Paper page
  4. X. Wang , et al., Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. medRxiv, 2020.04.15.20065623 (2020). · DOI
  5. T. F. Rogers , et al., Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science (New York, N.Y.) (2020) https:/doi.org/10.1126/science.abc7520. · DOI · Paper page
  6. 10.1016/j.it.2020.04.008 · DOI · Paper page
  7. 2020, Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals Highlights d SARS-CoV-2-specific antibodies are detected in COVID-19 convalescent subjects ll Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals, Immunity, 52, 971
  8. L. Bao , et al., Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv, 1–20 (2020).
  9. 10.3201/eid1111.040659 · DOI · Paper page
  10. Public Health England, “Chapter 6: Contraindications and special considerations” in The Green Book: Immunisation against Infectious Disease, (2017).
  11. J. R. Brown , L. Atkinson , D. Shah , K. Harris , Validation of an extraction-free RT-PCR protocol for detection of SARS-CoV2 RNA. medRxiv, 2020.04.29.20085910 (2020). · doi:10.1101/2020.04.29.20085910
  12. H. Hou , et al., Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clinical and Translational Immunology 9 (2020). · DOI · Paper page
  13. 10.3201/eid2206.160010 · DOI · Paper page
  14. 10.1056/NEJMc070348 · DOI · Paper page
  15. 10.3201/eid2210.160706 · DOI · Paper page
  16. A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction (2020) https:/doi.org/10.21203/rs.3.rs-24574/v1 (July 9, 2020). · doi:10.21203/rs.3.rs-24574/v1
  17. 10.1016/j.jtbi.2020.110254 · DOI
  18. 10.1038/s41467-020-15562-9 · DOI · Paper page
  19. 2020, Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections ll Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections, CellReports, 31, 107725
  20. P. Kellam , W. Barclay , The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. Journal of General Virology, jgv001439 (2020). · DOI
  21. 10.1016/j.cellimm.2020.104114 · DOI

Cited by

Metadata

Authors
Grandjean, L., Saso, A., Torres, A., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H., Ralph, E., Mai, A., Colijn, C., Breuer, J., Buckland, M., Gilmour, K., Goldblatt, D., & the Co-Stars Study Team
Venue
medRxiv
Publisher
openRxiv
Published
2020-07-21
OpenAlex
W3044593649
Cited by
45
References
21
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.